Links are not yet activated.
To activate, add a link back to submitpr.org from your website and contact @jaycosta on Telegram,
or pay via Solana (from $19.95) for instant activation.
Neuralink has begun testing its Telepathy brain-computer interface at National University Hospital in Singapore, marking the company's first clinical foothold in Asia as it shifts from small-scale trials to high-volume production of the implantable device.The expansion, confirmed in February 2026, positions Singapore as a regulatory gateway for Neuralink's push into Asian markets. The company now has 21 patients enrolled in global trials, up from 12 in September 2025, with zero serious device-related adverse events reported.
Neuralink implanted its first human patient, Noland Arbaugh, in January 2024. Arbaugh, who is paralyzed, has since demonstrated the ability to control phones and computers using only his thoughts through the Telepathy software interface.
The N1 implant contains 1,024 electrodes distributed across 64 ultra-thin threads, each narrower than a human hair. The company's R1 surgical robot can now insert each thread in 1.5 seconds, a speed improvement that underpins Neuralink's plans for automated, high-throughput surgery.
Elon Musk declared on January 1, 2026, that the year would mark the beginning of mass production and automated surgical procedures. The company raised $650 million in Series E funding in June 2025, pushing its valuation to $9 billion.
Singapore's Health Sciences Authority launched a Regulatory Innovation Corridor on January 5, 2026, creating a fast-track pathway for breakthrough medical technologies including brain-computer interfaces. The framework enabled Neuralink to begin test-bedding at NUH within weeks.
Professor Dean Ho, director of the Institute for Digital Medicine at the National University of Singapore, is leading the AI-driven analysis of neural signals collected from local trials. His team is focused on measuring the long-term efficacy and durability of the implant.
"The subsequent work will likely look at the efficacy and durability of the technology" beyond initial demonstrations, Ho said, tempering expectations while acknowledging the hardware's capabilities.
Professor Aymeric Lim of NUH said the technology could transform neurorehabilitation by promoting neuroplasticity and restoring motor function in stroke patients. Singapore's rapidly aging population makes such restoration technologies a national priority under the government's Healthier SG strategy.
The clinical focus in Singapore centers on stroke and spinal cord injury patients, a deliberate choice given the country's demographic pressures. One in four Singaporeans will be over 65 by 2030, creating urgent demand for technologies that restore autonomy.
For full coverage, visit https://www.linos.ai/technology/neuralink-telepathy-singapore-brain-interface-trials/
About Linos NEWS: Linos NEWS (https://www.linos.ai) delivers breaking news and in-depth analysis across politics, technology, business, science, health, world affairs, sports, and entertainment.